Early cessation and non-response are important and possibly related problems in growth hormone therapy: An OZGROW analysis

I.P. Hughes, Catherine Choong, Shoshana Rath, Helen Atkinson, A. Cotterill, W. Cutfield, P. Hofman, M. Harris

    Research output: Contribution to journalArticle

    5 Citations (Scopus)


    © 2016 Elsevier Ltd. Objective: To investigate growth hormone (GH) treatment and treatment cessation with respect to efficacy and efficiency. To identify factors that best classify or predict cessation type: completed treatment (CT), early cessation (EC), or non-response (NR). Design: Observational study (1990-2013) of the Australian GH Program comparing CT, EC, and NR groups with respect to demographic, clinical, and response criteria. All patients treated for GH deficiency (GHD; 909), short stature and slow growth (SSSG; 2144), and Turner Syndrome (TS; 626) were included. Information was retrieved from the OZGROW database. Results: 51.9% of patients were EC, 40.7% CT and 7.4% NR.Median treatment durations for NR patients were often longer than patients who completed treatment. EC and NR groups were both associated with poor growth response with males overrepresented.Socioeconomic status differentiated NR (higher) and EC (lower) groups. Conclusions: EC was observed at very high rates and appears, generally, to be a little-recognised but frequent problem in GH therapy.EC and delayed recognition of NR may be interrelated being differentiated by the decision to cease or continue treatment following poor response.Poor treatment compliance is likely a major causal factor in EC.Strategies to address poor response and compliance have been developed, however, given the scale of these problems, it may be that long acting GH formulations or individualized treatment need consideration.
    Original languageEnglish
    Pages (from-to)63-70
    Number of pages8
    JournalGrowth Hormone and IGF Research
    Publication statusPublished - 2016


    Cite this